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Objective: to measure serum concentrations of elastin-derived peptides (S-EDP) in patients with aneurysmal, occlusive
and ulcerative manifestations of atherosclerotic disease.
Materials and Methods: S-EDP concentrations were measured by a competitive enzyme-linked immunosorbent assay in
10 patients with infrarenal aneurysms 5 cm in diameter (AAA), 10 patients with distal aortic occlusive disease (AOD), 10
patients with symptomatic carotid stenosis ( 70%) and plaque ulceration (SCS) and a control group of 10 patients with
no similar specific manifestations of atherosclerotic disease (NAM).
Results: S-EDP concentrations (median, range) were significantly higher in patients with AAA (42 ng/ml, 35±52,
p5 0.001) and SCS (49 ng/ml, 37±60, p5 0.001) but not AOD (28 ng/ml, 22±38, p 0.240) compared to NAM
(26 ng/ml, 19±36) patients.
Conclusion: increased concentrations of S-EDP were associated with aneurysmal and ulcerative, but not occlusive,
manifestations of atherosclerosis.
Key Words: Elastin-derived peptides; Atherosclerosis; Abdominal aortic aneurysm; Aortic occlusive disease; Carotid
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There is increasing evidence that inflammation plays a
central role in the pathogenesis of atherosclerosis.1±9
The local inflammatory processes may be responsible
for plaque destabilisation leading to acute ischaemic
syndromes.10±12
An important component of the vascular extracel-
lular matrix is the fibrous protein elastin, which is
contributing to the rheological properties of vessels.
In health elastin degradation is extremely slow due to
extensive cross-linking13 having a half-life of about
70 years.
Degradation of arterial wall elastin is however, a
characteristic feature in atherogenesis.14 Degradation
products of elastin, elastin-derived peptides (EDP)
has previously been explored in relation to atheros-
clerosis15 and abdominal aortic aneurysms (AAA).16,17
Serum concentrations of EDP (S-EDP) are elevated
in atherosclerotic patients compared to healthy sub-
jects,18 and seem to reflect elastin turnover.19,20 Chil-
dren from families with a high risk of atherosclerosis
also have elevated concentrations of S-EDP.21
However, S-EDP concentrations among atheroscle-
rotic patients have shown great heterogeneity.18 ThisPlease address all correspondence to: E. Petersen, Department of
Surgery, UmeaÊ University Hospital, S-90185 UmeaÊ, Sweden.
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ity22,23 and manifestations of the atherosclerotic
lesions.
The aims of this study were to measure S-EDP in
patients with specific (dilatory, occlusive or ulcerative)
manifestations of atherosclerotic disease represented
by abdominal aortic aneurysms (AAA), aortic occlu-
sive disease (AOD) and symptomatic carotid stenosis
(SCS) and to test the hypothesis that these patients
have higher concentrations of S-EDP than patients
with no similar specific manifestations of atheroscler-
otic disease (NAM).
Materials
Serum samples were collected preoperatively from 10
patients with AAA, 10 patients with AOD, 10 patients
with SCS and 10 NAM patients admitted for a
non-vascular condition. Patient characteristics are pre-
sented in Table 1. The serum samples were immedi-
ately stored at ÿ 70 C until analysis.
According to the definitions of the Committee on
Vascular Lesions of the Council on Arteriosclerosis,
American Heart Association24 the AAA, AOD and
SCS patients are representing advanced atherosclero-
tic lesions of type VI. The AAA patients had asymp-
tomatic infrarenal aortic aneurysms with a diameter ofl rights reserved.
Table 1. Patient characteristics.
AAA
n 10
AOD
n 10
SCS
n 10
NAM
n 10
Gender M/F 7/3 6/4 8/2 7/3
Age (years) (median, range) 69 (59±84) 64 (50±74) 65 (53±75) 64 (50±70)
Current smoking (%) 2 (20) 2 (20) 2 (20) 2 (20)
COPD (%) 2 (20) 1 (10) 1 (10) 1 (10)
AAA: abdominal aortic aneurysm. AOD: aortic occlusive disease. SCS: symptomatic carotid stenosis;
NAM: without atherosclerotic manifestations. COPD: chronic obstructive pulmonary disease.
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sented intermittent claudication for more than one
year. Arteriography of the aorta showed distal aortic
occlusion. The SCS patients had symptoms of cerebral
embolization (transient ischaemic attack, amaurosis
fugax or minor stroke). All SCS patients included
had ulcerated plaques of the internal carotid artery.
The plaques caused a high-grade stenosis (70%
luminal narrowing) of the internal carotid artery,
determined by intra-arterial cerebral angiography
using the criteria of the North American Symptomatic
Carotid Endarterectomy Trial (NASCET).25 The
maximum period from latest cerebral symptoms to
surgery was 3 months.
Regarding symptoms and findings by duplex scan,
each individual study group had no specific mani-
festations of atherosclerosis characterising the other
groups. The control group, NAM, consisted of patients
admitted for cholecystectomy. None of the patients
had had any symptoms of atherosclerosis and a duplex
scan confirmed that no manifestations of atheroscler-
osis characterising the study groups were present.
Methods
Preparation of antibodies
Elastin from bovine neck ligaments was treated with
0.25 M oxalic acid at 90 C to get soluble alpha-elastin.
The alpha-elastin was dissolved in phosphate buffer
saline (PBS) to a concentration of 2 mg/ml, followed
by emulsion in an equal volume of Freund's complete
adjuvant. New Zealand White rabbits were immu-
nised by multiple subcutaneous injections using
complete Freund's adjuvant. Ten days after the last
injection, serum was collected and centrifuged. Immu-
noglobulins were purified using protein-A affinity
chromatography and dialyzed against PBS and stored
in a concentration of 2 mg/ml at 4 C.26
Competitive ELISA
The wells on a microtiter plate were coated with 100 ml
of a-elastin (1.25 mg/ml) in 0.1 M sodium carbonate,pH 9 and incubated for 12 h at 4 C. For generation of
a standard curve, anti-a-elastin antibodies (2 mg/ml)
in PBS containing 0.05% tween 20 and 7% bovine
serum albumin (PBST-7% BSA) were preincubated
with a variable concentration of a-elastin peptides
(0±120 ng/ml) in PBST-7% BSA for 36 h at 4 C. Sim-
ultaneously, cell culture medium was mixed with anti-
a-elastin antibodies (2 mg/ml) in PBST-7% BSA and
incubated for 36 h at 4 C. Two hundred ml of these
reactions were transferred to the a-elastin coated
microtiter plate in triplicate. Before adding the reac-
tions the plate was washed four times with 400 ml of
PBST in an automated plate washer (Labsystem Multi-
wash). The plate was incubated for 1 h at room tem-
perature and washed with PBST. Two hundred ml of
HRP-labeled donkey-anti-rabbit IgG antibody (1:4000,
Amersham Pharmacia Biotech, NA 934) were added
and incubated for 1 h at room temperature and washed
with PBST. Thereafter 200 ml of phosphate-citrate buffer,
pH 5.0, containing 2 mg/ml of o-phenylendiamine
dihydrochloride (Sigma, P7288) and 0.012% H2O2
were added and the plates were incubated in the
dark for 20 min at room temperature. Reactions were
stopped by adding 50 ml of 3 N HCl. Absorbency was
read at 492 nm using an automated plate reader
(Labsystem, Multiscan MS).17,27 The concentrations
of EDP were expressed as ng/ml.
The reproducibility and sensitivity of the ELISA are
presented in Table 2. The study was approved by the
Scientific Ethics Committee, UmeaÊ University.
Statistical Methods
The Statistical Package of the Social Sciences (SPSS for
Windows 11.0) was used. Results were reported as
median and range. Differences in categorical variables
were tested by Chi-square. Nonparametric analysis of
variance (Kruskal±Wallis one-way ANOVA by ranks)
and Mann±Whitney U-test were used to compare
S-EDP concentrations between the groups. As the
chance of a type one error is increased by multiple com-
parison a downward adjustment of a was made. As
six independent comparisons were made, statistical
significance was set at 99.2% (p5 0.008). AssumingEur J Vasc Endovasc Surg Vol 24, November 2002
Table 2. Sensitivity and reproducibility of the ELISA. Concentrations of S-EDP are expressed as ng/ml. The
sensitivity (minimal detectable dose) was defined as two standard deviations above the mean optical density
of zero standard replicates and by calculating the corresponding concentrations.
EDP sensitivity Within assay precision Between assay precision
n Mean SD CV (%) n Mean SD CV (%)
2.19 ng/ml 12 4.17 1.65 40 4 1.17 0.19 16
12 7.17 1.09 15 4 5.80 0.93 16
12 20.7 2.28 11 4 17.59 0.96 5
S-EDP: serum elastin-derived peptides; CV: coefficient of variability; ELISA: enzyme linked immunosorbent
assay.
Table 3. The concentrations (median, range) of S-EDP in the dif-
ferent groups and the p-values of multiple comparisons. Nonpara-
metric analysis of variance (Kruskal±Wallis one-way ANOVA by
ranks) and Mann±Whitney U-test were used to compare S-EDP
concentrations between the groups. As the chance of a type I error
is increased by multiple comparisons a downward adjustment of
a was made. As six independent comparisons were made, statis-
tical significance was set at 99.2% (p5 0.008).
AAA AOD SCS
42 ng/ml
(35±52)
28 ng/ml
(22±38)
49 ng/ml
(37±60)
NAM
26 ng/ml (19±36) p5 0.001 p 0.240 p5 0.001
SCS
49 ng/ml (37±60) p 0.103 p5 0.001
AOD
28 ng/ml (22±38) p 0.001
AAA: abdominal aortic aneurysm; AOD: aortic occlusive disease;
SCS: symptomatic carotid stenosis; NAM: without atherosclerotic
manifestations.
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groups, a number of 10 patients in each group would
allow a 90% chance of detecting a difference this large
at the chosen level of statistical significance (a 0.008)
(SPSS Sample Power).
Results
There were no significant differences between the
groups concerning age, gender, occurrence of chronic
obstructive pulmonary disease (COPD) or current
smoking. Statistically significant higher concentra-
tions of S-EDP (median, range) were measured in
AAA (42 ng/ml, 35±52, p5 0.001) and SCS (49 ng/ml,
37±60, p5 0.001) but not in AOD (28 ng/ml, 22±38,
p 0.240) patients compared to NAM (26 ng/ml,
19±36) patients. The concentrations of S-EDP were
even significantly higher in AAA (p 0.001) and
SCS (p5 0.001) patients compared to AOD patients
(Table 3).
Discussion
In the present study S-EDP concentrations were sig-
nificantly higher in both AAA and SCS patients com-
pared to NAM patients. The increased concentrations
of S-EDP in AAA disease are likely to be correlated
to the extensive degradation of elastin28,29 caused by
increased activity of elastolytic enzymes. S-EDP con-
centrations in SCS patients were expected to be higher
than in NAM patients, but it was surprising that EDP
concentrations were comparable to the concentrations
in AAA patients. This finding may indicate that elas-
tin degradation in an ulcerated atherosclerotic lesion
is very extensive. This is supported by the fact that
the area and mass of arterial tissue involved in the
atherosclerotic process is much smaller in SCS than in
AAA disease.
It has been shown that elastin degradation is more
extensive in AAA than in AOD,30,31 explaining signifi-
cantly higher S-EDP concentrations in AAA patientsEur J Vasc Endovasc Surg Vol 24, November 2002compared to AOD patients. However it was surpris-
ing that the S-EDP concentrations in AOD patients
were comparable to NAM patients as AOD patients
have general atherosclerosis. It is however possible
that the inflammatory process in a longstanding ath-
erosclerotic occlusion with time may `burn out'. Exclu-
sion of the occluded aortic segment from the blood
circulation may also contribute to lower concentra-
tions of S-EDP in AOD patients, as EDP cannot leak
from the lesion directly to the aortic blood circulation.
Normally the microcirculation has the largest contact
surface with tissues and most EDP may leak to the
blood circulation in this way. However, no vasa
vasorum is normally present in the distal abdominal
aorta making this passage less possible. The results of
the present study may therefore suggest that the main
leakage of EDP into the blood circulation goes directly
to the blood passing the lesion.
In atherosclerosis9 and especially AAA disease32±34
an inflammatory process with release of matrix metal-
loproteinases (MMP) from macrophages and smooth
muscle cells is involved in degradation of arterial
Serum Elastin-derived Peptides in Atherosclerosis 443elastin. Mature non-degraded elastin is hydrophobic,
whereas degraded elastin, EDP, is hydrophilic and
dissolves in the blood. The presence of EDP in serum
may reflect the intensity of the elastolytic process in
atherosclerotic lesions of the vasculature.15,18 EDP
have the ability to interact with various cells via the
elastin receptor35 and possesses several potential
harmful effects such as induction of monocyte
chemotaxis,36 elastase30 and MMP production and
activation,37 free radical release, LDL oxidation and
endogenous cholesterol production.38 As these pep-
tides are spread out in the whole body via the blood,
not only a local reaction to EDP in an atherosclerotic
lesion but a systemic reaction may be expected.
Recently, attention to EDP, its biological effects and
the importance in atherogenesis has increased.
Morbidity and mortality from atherosclerosis is
largely due to advanced lesions, such as type VI
atherosclerotic lesions, in which there are disruptions
of the lesion surface (type VIa), haematoma or
haemorrhage (type VIb), or thrombotic deposits
(type VIc).24 As elastolytic activity seems positively
correlated to the degree of the atherosclerotic lesion,22
it may be suggested that S-EDP hypothetically could
be an indicator of advanced atherosclerotic lesions in
elastic arteries and correlated to the risk of atheroscler-
otic complications. The relative high S-EDP concentra-
tions associated with a type VI atherosclerotic lesion
in the internal carotid artery as in SCS patients, may
suggest that patients with such lesions in the distal
abdominal aorta, preceding development AAA or
AOD, may give rise to even higher concentrations of
S-EDP. It is therefore possible that high concentrations
of S-EDP may be associated with pre-dilatory states
of AAA and pre-occlusive states of AOD or other
manifestations of atherosclerosis in progress. S-EDP
measurements of historical blood samples of patients
later developing AAA or AOD could be interesting.
Another interesting question is, whether S-EDP may
be used in surveillance of plaque stabilisation.
It is impossible to explore the whole vascular sys-
tem in a specific patient. As atherosclerosis is a sys-
temic disease it can not be excluded that advanced but
asymptomatic lesions in other locations in the vascu-
lature, which has not been investigated, may contri-
bute to the amount of S-EDP measured in the study
patients. In advanced atherosclerotic lesions smooth
muscle cells have the potential of synthesising the
precursor of elastin, tropoelastin. It is therefore pos-
sible that new synthesised elastin may contribute to
increase the level of S-EDP. However, elastin-mRNA
expression in AAA disease is not increased compared
to normal aorta39 and tropoelastin is believed to be
highly sensitive to proteolysis. Although the majorpart of the total elastin content of the human body is
located in the vasculature, degenerative diseases in
other organs containing elastin (skin or lungs) may
also increase S-EDP concentrations. COPD is asso-
ciated with increased concentrations of S-EDP.40
Even smoking may increase elastase activity in
arteries.41 However, in the present study there were
no significant differences in the occurrence of COPD
or current smoking between the groups (Table 1).
Results of the EVA-study42 suggest that there is a
negative correlation between EDP in plasma and risk
factors of atherogenesis as well as atherosclerosis-
related diseases. However, these correlations were
very weak and not present in both women and men.
Increased concentrations of S-EDP may be a pos-
sible indicator of advanced atherosclerosis, leaking
EDP direct into the blood circulation from disrupted
plaques. As morbidity and mortality from atheroscler-
osis is largely due to such lesions, EDP may also be a
possible risk indicator of atherosclerotic complica-
tions; however, further studies are needed.
In conclusion, increased concentrations of S-EDP
were associated with a dilatory and an ulcerative but
not with an occlusive manifestation of atherosclerosis,
represented by AAA, SCS and AOD respectively.
High concentrations of S-EDP may theoretically be
an indicator of advanced atherosclerosis and has to
be further investigated.
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